Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...

Lara Rodriguez Sanchez, Samir Taneja, Hashim Ahmed, Himanshu Nagar, Edward Schaeffer in a Crossfire: Controversies in Urology debate: discussed if Focal Therapy is a Suitable Option for all Cases with ...

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered. Based on new findings in ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Cancer survivors are banging the gong with gusto at Calgary’s new cancer centre. The outdoor gong reverberates through the ...

Pedro C. Barata, MD, MSc, discusses the use of darolutamide in patients with hormone-sensitive prostate cancer.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on ...

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.

Radiotherapy remains a fundamental treatment for prostate cancer, and recent developments in precision medicine and ...

The PRECISION study investigates a 3-fraction SBRT regimen for localized prostate cancer ... I am confident that we can demonstrate effective cancer treatment with less side effects," said Professor ...